Roswell Park believes the partnership could grant cancer patients early access to promising new treatments and provide a commercial development pathway for new discoveries.
Roswell Park and various New York agencies will provide Cleveland BioLabs with up to $5 million of non-dilutive funding. Cleveland BioLabs will establish a major research and clinical facility at the Roswell Park campus in Buffalo, New York. The company will also have an open-ended license to any basic research conducted within or in collaboration with its Roswell Park laboratory.
“They are offering a unique treatment platform and an extensive pipeline of cancer drug candidates in advanced development, including their phase II oral, cancer compound and family of radio-protectants. The company’s recent finding regarding proliferation of adult stem cells following administration of one of its radio-protectant compounds is particularly interesting,” stated Dr David Hohn, president & CEO of Roswell Park Cancer Institute.
Roswell Park hopes the partnership will grant cancer patients early access to promising new treatments and provide a commercial development pathway for new discoveries.